5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.28▲ | 1.26▲ | 1.26▲ | 1.24▲ | 1.33▼ |
MA10 | 1.27▲ | 1.23▲ | 1.24▲ | 1.26▲ | 1.54▼ |
MA20 | 1.24▲ | 1.24▲ | 1.24▲ | 1.33▼ | 2.09▼ |
MA50 | 1.23▲ | 1.27▲ | 1.28▲ | 1.61▼ | 4.85▼ |
MA100 | 1.29▼ | 1.28▲ | 1.34▼ | 2.19▼ | 15.51▼ |
MA200 | 1.30▼ | 1.42▼ | 1.56▼ | 3.34▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.006▲ | 0.009▲ | 0.009▲ | 0.013▲ | 0.253▲ |
RSI | 59.940▲ | 60.552▲ | 56.132▲ | 42.971▼ | 28.438▼ |
STOCH | 73.521 | 77.976 | 68.717 | 21.678 | 4.731▼ |
WILL %R | -18.182▲ | -16.667▲ | -16.667▲ | -70.000 | -91.892▼ |
CCI | 81.729 | 146.199▲ | 126.554▲ | -27.992 | -108.922▼ |
Wednesday, September 17, 2025 05:41 AM
Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical ...
|
Wednesday, September 10, 2025 05:48 AM
ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to ...
|
Thursday, September 04, 2025 05:33 AM
Detailed price information for Ernexa Therapeutics Inc (ERNA-Q) from The Globe and Mail including charting and trades.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
18/09/25 | 1.24 | 1.31 | 1.22 | 1.29 | 310,485 |
17/09/25 | 1.23 | 1.28 | 1.18 | 1.18 | 103,731 |
16/09/25 | 1.19 | 1.2896 | 1.19 | 1.245 | 84,837 |
15/09/25 | 1.29 | 1.32 | 1.17 | 1.18 | 190,803 |
12/09/25 | 1.39 | 1.3968 | 1.26 | 1.29 | 179,975 |
11/09/25 | 1.41 | 1.57 | 1.35 | 1.38 | 443,534 |
10/09/25 | 1.35 | 1.40 | 1.22 | 1.29 | 83,300 |
09/09/25 | 1.255 | 1.265 | 1.20 | 1.265 | 42,546 |
08/09/25 | 1.30 | 1.314 | 1.19 | 1.24 | 50,678 |
05/09/25 | 1.23 | 1.29 | 1.21 | 1.25 | 54,100 |
|
|
||||
|
|
||||
|
|